Literature DB >> 23162029

Extensive venous thrombosis in a healthy young man with a short inferior vena cava syndrome treated successfully with rivaroxaban.

Alhossain A Khalafallah1, Shamsunnaher Renu, Colin Sharp, Terry Hannan.   

Abstract

We report a case of an incidental finding of congenital absence of the intrahepatic segment of the inferior vena cava (IVC) complicated by extensive bilateral deep venous thrombosis (DVT) with significant oedema following a long-distance road trip. Initially the patient failed treatment with standard anticoagulation therapy with enoxaparin and warfarin. However, he has responded to the new oral antifactor-Xa anticoagulant (rivaroxaban). Within a few days, rivaroxaban improved the oedema and DVT. The significant features of this case are the unusual presentation, the poor response to initial standard anticoagulation therapy and the beneficial outcomes when managed with the novel new anticoagulant. The patient has continued the new treatment regularly for the last 12 months with good toleration and without side effects. This report presents the findings, management and outcomes in a case of extensive bilateral DVT in a previously healthy young man who was found to have a congenital short IVC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23162029      PMCID: PMC4543762          DOI: 10.1136/bcr-2012-007313

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

1.  Congenital absence of the inferior vena cava: a rare risk factor for idiopathic deep-vein thrombosis.

Authors:  M Ruggeri; A Tosetto; G Castaman; F Rodeghiero
Journal:  Lancet       Date:  2001-02-10       Impact factor: 79.321

2.  Anomalous inferior vena cava with azygos continuation (infrahepatic interruption of the inferior vena cava). Report of 15 new cases.

Authors:  R C ANDERSON; P ADAMS; B BURKE
Journal:  J Pediatr       Date:  1961-09       Impact factor: 4.406

3.  A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.

Authors:  F A Anderson; H B Wheeler; R J Goldberg; D W Hosmer; N A Patwardhan; B Jovanovic; A Forcier; J E Dalen
Journal:  Arch Intern Med       Date:  1991-05

Review 4.  Inferior vena cava agenesis and deep vein thrombosis: 10 patients and review of the literature.

Authors:  Marc Lambert; Philippe Marboeuf; Marco Midulla; Nathalie Trillot; Jean-Paul Beregi; Claire Mounier-Vehier; Pierre-Yves Hatron; Brigitte Jude
Journal:  Vasc Med       Date:  2010-12       Impact factor: 3.239

Review 5.  Deep vein thrombosis caused by congenial interruption of the inferior vena cava--a case report.

Authors:  Y Tsuji; T Inoue; H Murakami; Y Hino; H Matsuda; Y Okita
Journal:  Angiology       Date:  2001-10       Impact factor: 3.619

6.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

Authors:  Harry R Büller; Martin H Prins; Anthonie W A Lensin; Hervé Decousus; Barry F Jacobson; Erich Minar; Jaromir Chlumsky; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Alexander Cohen; Scott D Berkowitz; Henri Bounameaux; Bruce L Davidson; Frank Misselwitz; Alex S Gallus; Gary E Raskob; Sebastian Schellong; Annelise Segers
Journal:  N Engl J Med       Date:  2012-03-26       Impact factor: 91.245

Review 7.  Congenitally absent inferior vena cava presenting in adulthood with venous stasis and ulceration: a surgically treated case.

Authors:  M J Dougherty; K D Calligaro; D A DeLaurentis
Journal:  J Vasc Surg       Date:  1996-01       Impact factor: 4.268

8.  Perinatal inferior vena cava thrombosis and absence of the infrarenal inferior vena cava.

Authors:  T Ramanathan; T M Hughes; A J Richardson
Journal:  J Vasc Surg       Date:  2001-05       Impact factor: 4.268

9.  Anomalies of the inferior vena cava in patients with iliac venous thrombosis.

Authors:  Andrea Obernosterer; Manuela Aschauer; Wolfgang Schnedl; Rainer W Lipp
Journal:  Ann Intern Med       Date:  2002-01-01       Impact factor: 25.391

10.  Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.

Authors:  Alexander G G Turpie; Michael R Lassen; Bruce L Davidson; Kenneth A Bauer; Michael Gent; Louis M Kwong; Fred D Cushner; Paul A Lotke; Scott D Berkowitz; Tiemo J Bandel; Alice Benson; Frank Misselwitz; William D Fisher
Journal:  Lancet       Date:  2009-05-04       Impact factor: 79.321

View more
  3 in total

1.  The use of rivaroxaban in deep venous thrombosis associated with vena cava inferior agenesis.

Authors:  Ali Ahmet Arıkan; Selçuk Emre; Bayraktar Fatih Avni
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2019-10-23       Impact factor: 0.332

2.  Remarkable regression of massive deep vein thrombosis in response to intensive oral rivaroxaban treatment.

Authors:  Norimichi Koitabashi; Nogiku Niwamae; Tetsuya Taguchi; Yoshiaki Ohyama; Noriaki Takama; Masahiko Kurabayashi
Journal:  Thromb J       Date:  2015-03-14

3.  Effect of rivaroxaban on preventing deep vein thrombosis in aged diabetics with femoral neck fractures after hip replacement.

Authors:  Yi-Min Zhang; Xin Jiang; Yan-Shan Sun
Journal:  Biosci Rep       Date:  2017-06-21       Impact factor: 3.840

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.